Hematology/Oncology News

Bluebird Bio’s lentiviral vector gene therapy Skysona met its primary efficacy endpoint of survival without major functional disability in 81% of boys with early cerebral adrenoleukodystrophy, a recent analysis showed.

While Black patients are less likely to develop first melanoma than white patients, this group has a higher relative rate of secondary melanoma diagnosis, according to a study.

When investing, time in the market is arguably as important as well-publicized factors, such as rate of return, initial amount of investment (principal) and costs of investing.

Stage at diagnosis and survival among younger individuals with cancer varied considerably by race, according to a retrospective cohort study.

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial.

Innovative dosing strategies are warranted to improve the well-being of individuals with metastatic breast cancer, according to a patient advocate-led study published in JCO Oncology Practice.

The FDA approved inavolisib as part of combination therapy for certain adults with breast cancer.

Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.

Healio spoke with oncologist, past ASCO president and philanthropist, Sandra Swain, MD, FACP, FASCO, who helped establish Women Who Conquer Cancer.

Most physicians who conducted peer reviews for major medical journals received industry payments, according to a research letter published in JAMA.